The VENTANA CLDN18 (43-14A) RxDx Assay is the latest addition to Roche’s market-leading portfolio of IHC/ISH companion diagnostics designed to provide critical insights that enable more informed clinical decisions and improve patient outcomes. Detecting CLDN18.2 is key to determining eligibility for VYLOY® (zolbetuximab-clzb).
